87804

Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza

This CPT code (87804) represents a rapid point-of-care laboratory test used to detect the presence of the Influenza virus antigen directly from a clinical specimen. Typically, the specimen is obtained via a nasal swab, nasopharyngeal swab, or nasal wash/aspirate. The procedure utilizes an immunoassay technique that relies on direct optical (visual) observation, commonly referred to as a Rapid Influenza Diagnostic Test (RIDT). The mechanism of action involves the utilization of highly specific antibodies that bind to influenza viral nucleoproteins, specifically targeting either Influenza A, Influenza B, or both, depending on the test kit design. When the viral antigen is present in the patient respiratory specimen, it reacts with the specialized antibodies embedded in the test strip or cassette. This biochemical reaction produces a visible color change or the appearance of a distinct line that the performing clinician or laboratory technician can clearly see with the naked eye. Because this qualitative test does not require complex automated analytical instruments or extensive laboratory infrastructure, it is highly suitable and frequently deployed in point-of-care settings. These settings include urgent care clinics, primary care physician offices, pediatric clinics, and hospital emergency departments. The primary clinical utility of this procedure is to rapidly diagnose an active, acute influenza infection in symptomatic patients. These patients typically present with classic flu-like symptoms such as sudden high fever, chills, severe myalgia (muscle aches), headache, non-productive cough, sore throat, and profound fatigue, especially during the recognized peak flu season. Achieving a prompt diagnosis using CPT 87804 enables the timely and targeted initiation of antiviral medications, such as oseltamivir or zanamivir, which have been proven to be most clinically effective when administered within the critical first 48 hours of symptom onset. Additionally, the rapid and accurate detection of the influenza virus helps healthcare facilities implement appropriate isolation and infection control measures, thereby mitigating the risk of viral transmission to vulnerable populations. Furthermore, a confirmed viral diagnosis plays a crucial role in antibiotic stewardship programs by preventing the unnecessary prescription of antibiotics for what is confirmed to be a viral illness. Clinicians must be aware that while RIDTs offer excellent specificity (meaning false positives are rare), their sensitivity can be highly variable. False-negative results occur with some frequency, particularly if the patient viral load is low, if the specimen collection was suboptimal, or if the test is performed too early or too late in the disease course. Therefore, in scenarios where the clinical suspicion for influenza remains exceptionally high despite a negative rapid test result, clinical guidelines strongly recommend pursuing further confirmatory diagnostic testing utilizing more sensitive molecular methodologies, such as reverse transcription-polymerase chain reaction (RT-PCR) assays.

Clinical Indications

  • Acute onset of respiratory symptoms including cough, sore throat, and rhinorrhea.
  • Systemic symptoms suggestive of influenza such as sudden high fever, chills, severe myalgia, and fatigue.
  • Evaluation of symptomatic patients during a known influenza community outbreak or typical flu season.
  • Determining the need for targeted antiviral therapy (e.g., neuraminidase inhibitors) within the 48-hour therapeutic window.
  • Implementation of isolation and infection control protocols in institutional settings like hospitals, nursing homes, or schools.
  • Differentiation of influenza from other viral or bacterial respiratory pathogens to avoid inappropriate antibiotic use.

Procedure Steps

  1. Verify patient identity and ensure clinical indications align with the need for rapid influenza testing.
  2. Collect the clinical specimen using a sterile swab (nasal, nasopharyngeal, or throat) or by obtaining a nasal aspirate/wash, following manufacturer and clinical guidelines.
  3. Prepare the test cassette or dipstick provided in the specific Rapid Influenza Diagnostic Test (RIDT) kit.
  4. Extract the viral antigen by placing the swab into the provided extraction buffer tube and mixing thoroughly according to kit instructions.
  5. Apply the specified number of drops of the extracted specimen-buffer mixture onto the sample well of the testing device.
  6. Allow the test to develop at room temperature for the precise duration specified by the manufacturer (typically 10 to 15 minutes).
  7. Visually inspect the test device for the appearance of control and test lines.
  8. Interpret the results based on direct optical observation: positive (both control and test lines visible), negative (only control line visible), or invalid (no control line visible).
  9. Document the findings in the patient medical record and report the results to the attending provider.

Coding Guidelines

  • Use modifier QW if the test is performed in a facility with a CLIA Certificate of Waiver, as many rapid influenza tests are CLIA-waived.
  • If testing for multiple strains (e.g., Influenza A and Influenza B) using a single device that distinguishes between the two, report 87804 multiple times. Use modifier 59 on the second unit to indicate a distinct procedural service (e.g., 87804, 87804-59).
  • Do not report 87804 in conjunction with codes for the same infectious agent using different methodologies on the same specimen unless medically necessary and properly modified.
  • Code 87804 specifically requires direct optical (visual) observation. If an instrument or analyzer is used to read the result, consider alternative codes (e.g., 87490, 87502).
  • Ensure the diagnosis code (ICD-10) supports the medical necessity of the test, typically a code for influenza-like illness, exposure, or specific respiratory symptoms.

Associated ICD-10 Codes